

Special Issue

Metal-Based Prodrugs and Nanoparticles in Cancer Therapy

Message from the Guest Editors

Transition metal complexes have long been used to treat cancer but many concerns are responsible for the current stall in the field of metal anticancer drugs. Nowadays, one of the strategies is to convert them into inert prodrugs, so that they can travel to the tumour site unchanged and release the drug in its active form only there. Moreover, the development of novel nanodrug delivery systems have been attracting growing interests as allow to improve pharmacokinetic and pharmacodynamic properties and show more therapeutic efficacy and less potential toxicity. This Special Issue welcomes contributions dealing with synthetic methods for the realization of novel metallo-prodrugs, nanosystems and/or metallodrug in nanoparticles; analysis of pharmacokinetic and pharmacodynamic properties of metal-based prodrugs, chemotherapeutics or metal drugs encapsulated in nanostructures; in vitro or in vivo evaluation of therapeutic properties of metal-based prodrugs, nanoparticles and nanostructured materials functionalized with therapeutic metal complexes; Use of metal-pro drugs or/and nanoparticles in diagnosis, medical imaging, therapy and theranostics as well.

Guest Editors

Dr. Irina Naletova

Prof. Dr. Barbara Tomasello

Dr. Victor V. Pleshkan

Deadline for manuscript submissions

closed (10 August 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/105734

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).